REVIEW Telaprevir (VX-950), marketed under Incivek and Incivo brand names), is a drug for the treatment of hepatitis C co-developed by Vertex Pharmaceuticals and Johnson & Johnson. It is a member of a class of antiviral drugs known as protease inhibitors, specifically inhibiting the hepatitis C viral enzyme NS3.4A serine protease. Telaprevir is only indicated for use against hepatitis c genotype 1 viral infections.
REFERENCES
[1]
Summa V.VX-950 (Vertex/Mitsubishi). Curr Opin Investig Drugs. 2005 Aug;6(8):831-7.
[2]
Lin C, Kwong AD, Perni RB Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets. 2006 Mar;6(1):3-16.
[3]
Gentile I, Viola C, Borgia F, Castaldo G, Borgia G. Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem. 2009;16(9):1115-21.
[4]
Gentile I, Carleo MA, Borgia F, Castaldo G, Borgia G. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus. Expert Opin Investig Drugs. 2010 Jan;19(1):151-9.
All products are stocked and shipped from San Francisco Bay Area, California, USA.
⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.
Add to Favorites 
Delete from Favorites 
